Skip to content

Comparison Of Dexmedetomidine, Fentanyl And Lignocaine In Attenuation Of Hemodynamic Response To Direct Laryngoscopy And Intubation In Patient Undergoing Laparoscopic Cholecystectomy

Comparison Of Dexmedetomidine, Fentanyl And Lignocaine In Attenuation Of Hemodynamic Response To Direct Laryngoscopy And Intubation In Patient Undergoing Laparoscopic Cholecystectomy

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04138472
Enrollment
30
Registered
2019-10-24
Start date
2019-10-30
Completion date
2020-02-29
Last updated
2020-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Laparoscopic Cholecystectomy

Keywords

Dexmedetomidine, Fentanyl, Lignocaine, Laryngoscopy, Hemodynamic Response, Laparoscopic Cholecystectomy

Brief summary

Comparison Of Dexmedetomidine, Fentanyl And Lignocaine In Attenuation Of Hemodynamic Response To Direct Laryngoscopy And Intubation In Patient Undergoing Laparoscopic Cholecystectomy

Detailed description

Direct laryngoscopy and intubation are painful stimulus that activates sympathoadrenal discharge which results in intense cardiovascular reflex i.e. tachycardia and hypertension. In this study we will compare effects of intravenous dexmedetomidine, fentanyl and lidocaine for attenuation of these reflexes in patient undergoing laproscopic cholecystectomy. how these agents will effect hemodynamic response during pneumoperitoneum. Tertiary objective will be to observe sedation, perioperative complications and recovery in these patients.

Interventions

DRUGdexmedetomidine

intravenous dexmedetomidine 0.06mg/kg in 100ml normal saline 0.9% over 10minutes.

DRUGfentanyl

intravenous fentanyl at 2mcg/kg in 100ml saline over 10 minutes in induction room.

DRUGlidocaine

intravenous lidocaine 1.5mg/kg in 100ml saline over 10 minutes in induction room.

Sponsors

Dow University of Health Sciences
CollaboratorOTHER
Sana Urooj
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Subject)

Masking description

Patients do not know about the interventions.

Intervention model description

Randomized control trial

Eligibility

Sex/Gender
ALL
Age
20 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* ASA-I and ll patients * Male and female patient of age 20-70 years. * Undergoing Elective surgery * Intubation by skilled anesthetist of at least 2 years' experience * Intubation not more than 45 seconds

Exclusion criteria

* Patients with uncontrolled DM, HTN, IHD, endocrine or autonomic dysfunction * Pregnant and lactating females * Short thick neck with anticipated difficult intubation * Any sort of obstructive restrictive or reactive airway disease * Patient allergic to any of the study medications. * Obese patients, Narcotic addicts

Design outcomes

Primary

MeasureTime frameDescription
Heart rateat inductionHemodynamic responses (average heart rate beats a minute)
systolic blood pressureat inductionhermodynamic response (Top number will be assessed of blood pressure)
Diastolic blood pressureat inductionhermodynamic response (bottom number will be assessed of blood pressure)
mean atrial pressureat inductionHemodynamic responses (average blood pressure in an individual during a single cardiac cycle)
Oxygen saturation (SpO2)at inductionHemodynamic responses) (arterial oxy-hemoglobin saturation is measured non-invasively by a finger pulse oximeter or handheld pulse oximeter,

Secondary

MeasureTime frameDescription
Recovery assessmentat 10 minutes post operativelyAldret score use for recovery assessment, it consist of 0-10 point where 0 indicates worst(no response) and 10 indicates good response
Complications1 week Post-operative(Operation -discharge)Cough, Laryngospasm, Bradycardia, Regugitation, PONV, Hypertention, Hypotension
Sedation assessmentat 10 minutes post operativeRamsey score use for sedation, it consist of 1-6 where 6 indicates worst(no response) and 6 indicates good response

Countries

Pakistan

Contacts

Primary ContactSana Urooj, FCPS
dr.sanaurooj@yahoo.com+923333515690
Backup ContactSana Urooj
dr.sanaurooj@yahoo.com03333515690

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026